Acer Therapeutics is a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for rare and life-threatening diseases. Co.'s pipeline includes four programs: ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders and Maple Syrup Urine Disease; ACER-801 (osanetant) for the treatment of induced vasomotor symptoms; EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome in patients with a confirmed type III collagen mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of viruses, including cytomegalovirus, zika, dengue, ebola and COVID-19. The ACER stock yearly return is shown above.
The yearly return on the ACER stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ACER annual return calculation with any dividends reinvested as applicable (on ex-dates).
|